Changes in the white blood cell count. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

Changes in the hemoglobin. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

WBC and ANC on day 7 post-chemotherapy. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

General clinical data of 88 patients with NPC. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

CONSORT participant flow diagram. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

S4 File - by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

Source data - by Desheng Xie (21439869)

Subjects:

Increased or reduced ATGL-1 activity does not significantly change <i>N. parisii</i> growth. by Hala Tamim El Jarkass (16625309)

Subjects:

Significant Wilcoxon test results of the Task 1 Nasa TLX data, differences between feedback ON and OFF. by Mucahit Gemici (21519313)

Chitosan-Based Thermal-Coagulation Hydrogel System Driven by Multiple Interactions: Oxidation-Induced Fast Gelation and Enhanced Performance by Yifan Liu (219681)

Subjects:

Probability of Cost-Effectiveness Across CET. by Yiping An (20609789)

Subjects:

Base-case analysis. by Yiping An (20609789)

Subjects:

Chitosan-Based Thermal-Coagulation Hydrogel System Driven by Multiple Interactions: Oxidation-Induced Fast Gelation and Enhanced Performance by Yifan Liu (219681)

Subjects:

Cost-effectiveness acceptability curve. by Yiping An (20609789)

Subjects:

Markov model. by Yiping An (20609789)

Subjects:

Incremental cost-effectiveness scatter plot. by Yiping An (20609789)

Subjects:

One-way sensitivity analysis. by Yiping An (20609789)

Subjects:

ICER changes with time horizon. by Yiping An (20609789)

Subjects:

Chitosan-Based Thermal-Coagulation Hydrogel System Driven by Multiple Interactions: Oxidation-Induced Fast Gelation and Enhanced Performance by Yifan Liu (219681)

Subjects:

Free diagram of forces exerted on the control mass . by Amirhossein Favakeh (21417884)

Subjects: